Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy

Figure 5

Western blot analysis of total and activation of the EGFR, Src, Akt, and MAPK in hMSC-TERT4 and hMSC-TERT20-CE8 which is clonal cell line derived from mesenchymal (stromal) stem cells and with the ability to form sarcoma-like tumours in mice. The cell lines were treated for 72 h with either vehicle, erlotinib 5 μM, or dasatinib 5 μM. t, total; p, phosphorylated. Histone H3 was used as loading control. For quantification data, see supplementary Figure  3.